title: Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine.
abstract: The authors explored the binge eating symptomatology in 74 patients receiving clozapine (N = 57) or olanzapine (N = 17), and compared body mass index (BMI, kg/m(2)) and weight gain in patients with and without binge eating symptomatology. Subjects who screened positively for binge eating were interviewed using a modified version of the Questionnaire on Eating and Weight Patterns (QEWP). Current BMIs were assessed cross-sectionally, BMIs at initiation of clozapine/olanzapine treatment retrospectively. Thirty-seven subjects (50%) screened positively. Taking clozapine and olanzapine together, 6/27 (22.2%) females and 3/47 (6.4%) males fulfilled criteria for binge eating disorder, 3/27 (11.1%) females and 2/47 (4.3%) males for bulimia nervosa. Patients who screened positively showed higher current BMIs (26.8 +/- 3.9 vs. 24.7 +/- 3.7 kg/m(2)) and higher BMI increments during clozapine/olanzapine treatment (3.9 +/- 3.1 vs. 2.6 +/- 3.4 kg/m(2)) than patients who screened negatively. We conclude that clozapine/olanzapine may induce binge eating and full blown eating disorders which may have predictive value for weight gain. For future research in this field we suggest a novel DSM-IV research classification "Medication-induced eating disorders".
authors.affiliation: Clinical Research Group, Department of Child and Adolescent Psychiatry, University of Marburg, Marburg, Federal Republic of Germany. frank.theisen@med.uni-marburg.de
authors.forename: F M
authors.initials: FM
authors.lastname: Theisen
authors.forename: A
authors.initials: A
authors.lastname: Linden
authors.forename: I R
authors.initials: IR
authors.lastname: König
authors.forename: M
authors.initials: M
authors.lastname: Martin
authors.forename: H
authors.initials: H
authors.lastname: Remschmidt
authors.forename: J
authors.initials: J
authors.lastname: Hebebrand
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines; D015992:Body Mass Index; D002032:Bulimia / Q000139:chemically induced*; D003024:Clozapine / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006963:Hyperphagia / Q000139:chemically induced*; D008297:Male; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects* / Q000031:analogs & derivatives*; D012307:Risk Factors; D011795:Surveys and Questionnaires; D015430:Weight Gain / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D003024:Clozapine; D000077152:Olanzapine